Holen Sie sich die Stockscreener-App
1.74
7.81%
0.14
Schlusskurs vom Vortag:
$1.60
Offen:
$1.63
24-Stunden-Volumen:
197.03K
Relative Volume:
3.14
Marktkapitalisierung:
$3.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.85M
KGV:
-0.1078
EPS:
-16.1435
Netto-Cashflow:
$-15.72M
1W Leistung:
-3.09%
1M Leistung:
-6.76%
6M Leistung:
-45.92%
1J Leistung:
+273.54%
1-Tages-Spanne:
$1.51
$2.01
1-Wochen-Bereich:
$1.51
$2.01
52-Wochen-Spanne:
$0.2701
$13.40
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Firmenname
Indaptus Therapeutics Inc
Sektor
Branche
Telefon
(646) 427-2727
Adresse
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
1.725 | 3.59M | 0 | -20.85M | -15.72M | -16.14 |
VRTX
Vertex Pharmaceuticals Inc
|
433.58 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.40 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.05 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.89 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.74 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Indaptus Therapeutics Inc Aktie (INDP) Neueste Nachrichten
Indaptus Therapeutics Appoints Yu Ding as New Chief Financial Officer Effective April 2026 - Minichart
Indaptus Therapeutics Names New CFO, Refreshes Board Oversight - The Globe and Mail
Indaptus Therapeutics announces CFO transition and new board appointment - Investing.com
INDP Technical Analysis & Stock Price Forecast - Intellectia AI
Indaptus appoints Yu Ding as CFO; Nir Sassi resigns - TradingView
Indaptus Therapeutics (INDP) names new CFO and independent director - Stock Titan
Indaptus Therapeutics Inc. (INDP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Yun Yao converts preferred into 41.99M Indaptus (INDP) shares - Stock Titan
SINO LION VENTURES (INDP) discloses 38.9M-share Indaptus stake via preferred conversion - Stock Titan
Indaptus (INDP) CEO converts preferred stock into 11.25M common shares - Stock Titan
Volatility Watch: Is Indaptus Therapeutics Inc stock undervalued right now2026 Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Risk Hedge: Whats next for Indaptus Therapeutics Inc stock2026 Action & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Revenue Check: Why is Indaptus Therapeutics Inc stock going upTrade Risk Assessment & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
New investor group takes large control stake in Indaptus Therapeutics (INDP) - Stock Titan
Yun Yao Leads Investor Group, Secures CEO Change at Indaptus Therapeutics, Inc. with 37.8% Stake - TradingView
Market Pulse: Why is Indaptus Therapeutics Inc stock going downWeekly Risk Summary & Safe Entry Zone Tips - baoquankhu1.vn
Rate Cut: Should I hold or sell Indaptus Therapeutics Inc nowTrade Analysis Report & AI Powered Market Entry Ideas - baoquankhu1.vn
Indaptus Therapeutics : 10-K 2025 Annual Report - marketscreener.com
Insider Buyers Lose US$40k As Indaptus Therapeutics Sheds US$583k - simplywall.st
Indaptus Therapeutics, Inc. Files Form 8-K Reporting Changes in Control – Key SEC Filing Details 3 - Minichart
Indaptus Therapeutics (INDP) shifts control and names Junyi Dai CEO-Chair - Stock Titan
Indaptus Therapeutics, Inc. Announces CEO Changes - MarketScreener
Lazar cuts Indaptus (NASDAQ: INDP) preferred stake, resigns as co‑CEO but stays on board - Stock Titan
Indaptus (INDP) director exits Series AAA stake, trims Series AA - Stock Titan
Short Covering: Does Indaptus Therapeutics Inc have declining or rising EPS2026 Major Catalysts & Safe Entry Zone Identification - baoquankhu1.vn
Market Outlook: Does Indaptus Therapeutics Inc have declining or rising EPSPortfolio Performance Report & Trade Opportunity Analysis Reports - baoquankhu1.vn
Indaptus Therapeutics, Inc. 2025 Annual Report: Company Overview, Risks, Investment Transaction, and Regulatory Compliance - Minichart
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Lazar-backed Indaptus Therapeutics (NASDAQ: INDP) halts trials, eyes strategic deal - Stock Titan
CEO Change: Will PANL stock hit new highs in YEAR2026 Sector Moves & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Published on: 2026-03-17 18:45:40 - baoquankhu1.vn
Indaptus Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
INDPIndaptus Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Indaptus Therapeutics (INDP) Stock Analysis Report | Financials & Insights - Benzinga Japan
Why Indaptus Therapeutics Inc. stock remains on buy listsWeekly Stock Report & Safe Entry Momentum Tips - Naître et grandir
Will Indaptus Therapeutics Inc. stock keep outperforming rivalsWeekly Trade Summary & Safe Entry Zone Identification - Naître et grandir
Indaptus Therapeutics Inc expected to post a loss of $4.36 a shareEarnings Preview - TradingView
Does Indaptus Therapeutics Inc. have declining or rising EPSPortfolio Profit Report & Daily Stock Momentum Reports - Mfd.ru
Why Did INDP Stock Gain 12% Today? - Stocktwits
Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Thursday - Defense World
CapEx per share of Indaptus Therapeutics, Inc. – NASDAQ:INDP - TradingView
Lazar takes 98% control stake in Indaptus Therapeutics (INDP) via $6M deal - Stock Titan
Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement - marketscreener.com
Indaptus Shareholders Approve Major Charter and Capital Changes - The Globe and Mail
Indaptus Therapeutics shareholders approve preferred stock conversion and company charter amendments - Investing.com
Indaptus (INDP) director Jerome Jabbour awarded options on 25,000 shares - Stock Titan
Indaptus Therapeutics (NASDAQ: INDP) investors back control shift, share boost - Stock Titan
Indaptus Therapeutics (INDP) director Jerome Jabbour files initial Form 3 - Stock Titan
Rate Hike: Why is Indaptus Therapeutics Inc stock going up2025 Trading Recap & Weekly Stock Performance Updates - baoquankhu1.vn
Indaptus Therapeutics (INDP) director discloses holding 25,000 common shares - Stock Titan
INDP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Finanzdaten der Indaptus Therapeutics Inc-Aktie (INDP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):